Previous 10 | Next 10 |
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with ...
2023-03-20 13:07:07 ET Gainers: Loyalty Ventures ( LYLT ) +97% . Ambipar Emergency ( AMBI ) +73% . Lifecore Biomedical ( LFCR ) +60% . InMed Pharmaceuticals ( INM ) +43% . New York Community Bancorp ( NYCB ) +32% . Harbor Cus...
2023-03-20 10:29:09 ET Gainers: Lifecore Biomedical ( LFCR ) +41% . Connect Biopharma ( CNTB ) +27% . InMed Pharmaceuticals ( INM ) +21% . ReShape Lifesciences ( RSLS ) +21% . Bellerophon Therapeutics ( BLPH ) +15% . Losers...
2023-03-08 08:46:06 ET Intelligent Bio Solutions ( INBS ) -48% on proposed public offering . Castor Maritime ( CTRM ) -36% . Miromatrix Medical ( MIRO ) -32% on pricing $10M stock offering . United Natural Foods ( UNFI ) -22% on Q2...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 08:44:37 ET Bellerophon Therapeutics ( NASDAQ: BLPH ) entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares at $2/share and 1.78M prefunded warrants at a price of ...
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered ...
Gainers: Cardio Diagnostics ( CDIO ) +135% . Bioventus ( BVS ) +64% . Sky Harbour Group ( SKYH ) +36% . RenovoRx ( RNXT ) +24% . Bellerophon ( BLPH ) +24% . SI-BONE ( SIBN ) +23% . Chico's FAS ( CHS ) +21% . Kon...
Bellerophon Therapeutics ( NASDAQ: BLPH ) announced the clearance of its Investigational New Drug ( IND ) application to conduct a Phase 3 clinical trial of INOpulse to treat fibrotic interstitial lung disease (fILD) in China. ( BLPH ) is trading 4.2% higher prem...
WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Inve...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Bellerophon Therapeutics Inc. (BLPH) is expected to report for Q3 2023